Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).

1 finding from 1 review

Major bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Symptomatic PE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).

1 finding from 1 review

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).

1 finding from 1 review

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).

1 finding from 1 review

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).

1 finding from 1 review